Thromboxane b2

Thromboxane b2 is a lipid of Fatty Acyls (FA) class. Thromboxane b2 is associated with abnormalities such as endothelial dysfunction, Diabetes Mellitus, Non-Insulin-Dependent, Diabetes Mellitus, Ischemia and Thrombocytosis. The involved functions are known as Platelet Activation, Excretory function, Anabolism, Inflammation and mRNA Expression. Thromboxane b2 often locates in Endothelium, Hepatic and Microsomes, Liver. The associated genes with Thromboxane b2 are PTGS2 gene, prothrombin fragment 2 and CCL14 wt Allele.

Cross Reference

Introduction

To understand associated biological information of Thromboxane b2, we collected biological information of abnormalities, associated pathways, cellular/molecular locations, biological functions, related genes/proteins, lipids and common seen animal/experimental models with organized paragraphs from literatures.

What diseases are associated with Thromboxane b2?

Thromboxane b2 is suspected in endothelial dysfunction, Diabetes Mellitus, Non-Insulin-Dependent, Diabetes Mellitus, Ischemia, Thrombocytosis, Acute Coronary Syndrome and other diseases in descending order of the highest number of associated sentences.

Related references are mostly published in these journals:

Disease Cross reference Weighted score Related literature
Loading... please refresh the page if content is not showing up.

Possible diseases from mapped MeSH terms on references

We collected disease MeSH terms mapped to the references associated with Thromboxane b2

MeSH term MeSH ID Detail
Abortion, Habitual D000026 5 associated lipids
Acidosis D000138 13 associated lipids
Adenocarcinoma D000230 166 associated lipids
Agranulocytosis D000380 7 associated lipids
Airway Obstruction D000402 13 associated lipids
Albuminuria D000419 18 associated lipids
Alcoholic Intoxication D000435 15 associated lipids
Anaphylaxis D000707 35 associated lipids
Anemia D000740 21 associated lipids
Anemia, Sickle Cell D000755 34 associated lipids
Angina Pectoris D000787 27 associated lipids
Angina Pectoris, Variant D000788 3 associated lipids
Angina, Unstable D000789 14 associated lipids
Hypoxia D000860 23 associated lipids
Aortic Aneurysm D001014 8 associated lipids
Aortic Arch Syndromes D001015 2 associated lipids
Aortic Rupture D001019 3 associated lipids
Arrhythmias, Cardiac D001145 42 associated lipids
Arterial Occlusive Diseases D001157 12 associated lipids
Arteriosclerosis D001161 86 associated lipids
Arteriosclerosis Obliterans D001162 8 associated lipids
Arthritis D001168 41 associated lipids
Arthritis, Experimental D001169 24 associated lipids
Arthritis, Juvenile D001171 8 associated lipids
Arthus Reaction D001183 8 associated lipids
Ascites D001201 25 associated lipids
Asthenia D001247 5 associated lipids
Asthma D001249 52 associated lipids
Atrial Fibrillation D001281 16 associated lipids
Autoimmune Diseases D001327 27 associated lipids
Bartter Syndrome D001477 5 associated lipids
Behcet Syndrome D001528 7 associated lipids
Biliary Tract Neoplasms D001661 7 associated lipids
Birth Weight D001724 23 associated lipids
Blister D001768 16 associated lipids
Blood Platelet Disorders D001791 12 associated lipids
Bluetongue D001819 1 associated lipids
Body Weight D001835 333 associated lipids
Bronchial Spasm D001986 18 associated lipids
Bronchitis D001991 6 associated lipids
Bronchopneumonia D001996 7 associated lipids
Bronchopulmonary Dysplasia D001997 4 associated lipids
Bronchopulmonary Sequestration D001998 3 associated lipids
Burns D002056 34 associated lipids
Byssinosis D002095 11 associated lipids
Carbon Monoxide Poisoning D002249 9 associated lipids
Carcinoma, Non-Small-Cell Lung D002289 72 associated lipids
Cardiovascular Diseases D002318 24 associated lipids
Cat Diseases D002371 12 associated lipids
Cattle Diseases D002418 24 associated lipids
Celiac Disease D002446 16 associated lipids
Cell Transformation, Neoplastic D002471 126 associated lipids
Intracranial Embolism and Thrombosis D002542 5 associated lipids
Cerebral Hemorrhage D002543 13 associated lipids
Brain Ischemia D002545 89 associated lipids
Ischemic Attack, Transient D002546 42 associated lipids
Cerebrovascular Disorders D002561 25 associated lipids
Chediak-Higashi Syndrome D002609 4 associated lipids
Chest Pain D002637 4 associated lipids
Choline Deficiency D002796 16 associated lipids
Cleft Palate D002972 9 associated lipids
Colitis D003092 69 associated lipids
Colonic Neoplasms D003110 161 associated lipids
Contusions D003288 3 associated lipids
Coronary Artery Disease D003324 47 associated lipids
Coronary Disease D003327 70 associated lipids
Coronary Thrombosis D003328 7 associated lipids
Coronary Vasospasm D003329 9 associated lipids
Cough D003371 19 associated lipids
Death, Sudden D003645 12 associated lipids
Dermatitis, Atopic D003876 19 associated lipids
Diabetes Mellitus D003920 90 associated lipids
Diabetes Mellitus, Experimental D003921 85 associated lipids
Diabetes Mellitus, Type 1 D003922 56 associated lipids
Diabetes Mellitus, Type 2 D003924 87 associated lipids
Diabetic Angiopathies D003925 20 associated lipids
Diabetic Nephropathies D003928 39 associated lipids
Diabetic Retinopathy D003930 39 associated lipids
Diseases in Twins D004200 4 associated lipids
Disseminated Intravascular Coagulation D004211 7 associated lipids
Drowning D004332 2 associated lipids
Ductus Arteriosus, Patent D004374 5 associated lipids
Edema D004487 152 associated lipids
Edema, Cardiac D004489 1 associated lipids
Embolism, Fat D004620 4 associated lipids
Endometriosis D004715 29 associated lipids
Enteritis D004751 8 associated lipids
Erythromelalgia D004916 1 associated lipids
Escherichia coli Infections D004927 17 associated lipids
Eye Burns D005126 13 associated lipids
Facial Pain D005157 5 associated lipids
Fatty Liver D005234 48 associated lipids
Femoral Fractures D005264 7 associated lipids
Fetal Diseases D005315 8 associated lipids
Fever D005334 35 associated lipids
Fibromuscular Dysplasia D005352 2 associated lipids
Fibrosis D005355 23 associated lipids
Fistula D005402 8 associated lipids
Foot Rot D005535 1 associated lipids
Frostbite D005627 1 associated lipids
Per page 10 20 50 100 | Total 293

PubChem Associated disorders and diseases

What pathways are associated with Thromboxane b2

There are no associated biomedical information in the current reference collection.

PubChem Biomolecular Interactions and Pathways

Link to PubChem Biomolecular Interactions and Pathways

What cellular locations are associated with Thromboxane b2?

Related references are published most in these journals:

Location Cross reference Weighted score Related literatures
Loading... please refresh the page if content is not showing up.

What functions are associated with Thromboxane b2?


Related references are published most in these journals:

Function Cross reference Weighted score Related literatures

What lipids are associated with Thromboxane b2?

There are no associated biomedical information in the current reference collection.

What genes are associated with Thromboxane b2?

Related references are published most in these journals:


Gene Cross reference Weighted score Related literatures

What common seen animal models are associated with Thromboxane b2?

There are no associated biomedical information in the current reference collection.

NCBI Entrez Crosslinks

All references with Thromboxane b2

Download all related citations
Per page 10 20 50 100 | Total 6367
Authors Title Published Journal PubMed Link
Ersöz G et al. Effect of submaximal and incremental upper extremity exercise on platelet function and the role of blood shear stress. 2002 Thromb. Res. pmid:12676189
Bradlow BA and Chetty N Dosage frequency for suppression of platelet function by low dose aspirin therapy. 1982 Thromb. Res. pmid:7123514
Buchanan MR et al. Aspirin inhibits platelet function independent of the acetylation of cyclo-oxygenase. 1982 Thromb. Res. pmid:7071811
Butler KD et al. Prolongation of platelet survival in hypercholesterolaemic rabbits by CGS 12970 (3-methyl-2-(3-pyridyl)-1 indoleoctanoic acid) and dazoxiben. 1987 Thromb. Res. pmid:3109067
Grauso F et al. Effects of iloprost (ZK 36374), a prostacyclin derivative, on platelet function after ischaemic exercise in patients with stable angina pectoris. 1987 Thromb. Res. pmid:2447664
Jørgensen KA et al. The survival of pig to rabbit renal xenografts during inhibition of thromboxane synthesis. 1983 Thromb. Res. pmid:6364449
Naran NH and Chetty N The in vitro effect of ridogrel on platelet function in normocholesterolaemic and familial hypercholesterolaemic type IIa subjects. 1997 Thromb. Res. pmid:9556227
Kudolo GB et al. Effect of the ingestion of Ginkgo biloba extract on platelet aggregation and urinary prostanoid excretion in healthy and Type 2 diabetic subjects. 2002 Thromb. Res. pmid:12590952
Todd MH et al. The involvement of prostaglandins and thromboxanes in the response to pulmonary embolism in anaesthetized rabbits and isolated perfused lungs. 1983 Thromb. Res. pmid:6687961
Togna GI et al. Cisplatin triggers platelet activation. 2000 Thromb. Res. pmid:10973681
Grimm LJ et al. Inhibition of platelet thromboxane synthesis by 7-(1-imidazolyl) heptanoic acid: dissociation from inhibition of aggregation. 1981 Thromb. Res. pmid:6801806
Hashizume T et al. Vinblastine inhibits platelet aggregation by a microtubule-independent mechanism, probably by its perturbing action on the plasma membrane. 1988 Thromb. Res. pmid:3135636
Shatoor AS et al. Effect of Hawthorn (Crataegus aronia syn. Azarolus (L)) on platelet function in albino Wistar rats. 2012 Thromb. Res. pmid:22261477
Ito T et al. Role of activated platelets in endotoxin-induced DIC in rats. 1990 Thromb. Res. pmid:2080492
Han P et al. Inhibition of platelet function of antiarrhythmic drugs, verapamil and disopyramide. 1982 Thromb. Haemost. pmid:7101234
Greer IA et al. A comparative study of the effects of adrenoceptor antagonists on platelet aggregation and thromboxane generation. 1985 Thromb. Haemost. pmid:2867620
Miller KW and Keith JC Effect of thromboxane synthetase inhibition on platelet function and morphology during ovine pregnancy-induced hypertension. 1988 Thromb. Haemost. pmid:3238644
Teng CM et al. ADP-mimicking platelet aggregation caused by rugosin E, an ellagitannin isolated from Rosa rugosa Thunb. 1997 Thromb. Haemost. pmid:9066010
Santilli F et al. Effects of high-amount-high-intensity exercise on in vivo platelet activation: modulation by lipid peroxidation and AGE/RAGE axis. 2013 Thromb. Haemost. pmid:24030807
di Minno G et al. Effects of any epoxymethano stable analogue of prostaglandin endoperoxides (U-46619) on human platelets. 1981 Thromb. Haemost. pmid:6266066
Jilma-Stohlawetz P et al. Impaired platelet function among platelet donors. 2001 Thromb. Haemost. pmid:11583322
Dejana E et al. Bleeding time in rats: a comparison of different experimental conditions. 1982 Thromb. Haemost. pmid:6753230
Strano A et al. Platelet sensitivity to prostacyclin and thromboxane production in hyperlipidemic patients. 1982 Thromb. Haemost. pmid:6753232
Swartz SL and Moore TJ Effect of angiotensin II on collagen-induced platelet activation in normotensive subjects. 1990 Thromb. Haemost. pmid:2339363
Lepäntalo A et al. Polymorphisms of COX-1 and GPVI associate with the antiplatelet effect of aspirin in coronary artery disease patients. 2006 Thromb. Haemost. pmid:16493486
Matsumoto M et al. Thromboxane generation in patients with essential hypertension or cerebrovascular disease and effect of oral aspirin. 1980 Thromb. Haemost. pmid:7423441
Carter AJ et al. A comparison of human pulmonary arterial and venous prostacyclin and thromboxane synthesis--effect of a thromboxane synthase inhibitor. 1984 Thromb. Haemost. pmid:6377567
Spectre G et al. Twice daily dosing of aspirin improves platelet inhibition in whole blood in patients with type 2 diabetes mellitus and micro- or macrovascular complications. 2011 Thromb. Haemost. pmid:21800009
Honey AC et al. Effect of indomethacin and dazoxiben on intravascular platelet aggregation in the anaesthetized rabbit. 1986 Thromb. Haemost. pmid:3775692
Kyrle PA et al. Investigation of the interaction of blood platelets with the coagulation system at the site of plug formation in vivo in man--effect of low-dose aspirin. 1987 Thromb. Haemost. pmid:2954260
Gresele P et al. Picotamide protects mice from death in a pulmonary embolism model by a mechanism independent from thromboxane suppression. 1990 Thromb. Haemost. pmid:2274931
Krishnamurthi S et al. Effect of pyridoxal 5'-phosphate (PALP) on human platelet aggregation, dense granule release and thromboxane B2 generation--role of Schiff base formation. 1982 Thromb. Haemost. pmid:6891107
Essien EM et al. Blood changes and enhanced thromboxane and 6-keto prostaglandin F1 alpha production in experimental acute Plasmodium bergei infection in hamsters. 1984 Thromb. Haemost. pmid:6388013
Martinuzzo ME et al. Antiphospholipid antibodies enhance thrombin-induced platelet activation and thromboxane formation. 1993 Thromb. Haemost. pmid:8115993
Kyrle PA et al. Thromboxane A2 and prostacyclin generation in the microvasculature of patients with atherosclerosis--effect of low-dose aspirin. 1989 Thromb. Haemost. pmid:2508252
Larson MK et al. Effects of omega-3 acid ethyl esters and aspirin, alone and in combination, on platelet function in healthy subjects. 2008 Thromb. Haemost. pmid:18841286
Scharf RE In vitro thromboxane synthesis of depleted blood platelets following renal transplantation. 1990 Thromb. Haemost. pmid:2148845
Hoet B et al. Ridogrel, a combined thromboxane synthase inhibitor and receptor blocker, decreases elevated plasma beta-thromboglobulin levels in patients with documented peripheral arterial disease. 1990 Thromb. Haemost. pmid:2148849
Cattaneo M et al. Human platelet aggregation and release reaction induced by platelet activating factor (PAF-acether)--effects of acetylsalicylic acid and external ionized calcium. 1985 Thromb. Haemost. pmid:3927505
Wang WJ and Huang TF A novel tetrameric venom protein, agglucetin from Agkistrodon acutus, acts as a glycoprotein Ib agonist. 2001 Thromb. Haemost. pmid:11686327
Jackson C et al. DN 9693: a phosphodiesterase inhibitor with a platelet membrane effect. 1989 Thromb. Haemost. pmid:2546286
Davì G et al. Increased thromboxane metabolites excretion in liver cirrhosis. 1998 Thromb. Haemost. pmid:9569186
Sheu JR et al. Mechanisms involved in the antiplatelet activity of Staphylococcus aureus lipoteichoic acid in human platelets. 2000 Thromb. Haemost. pmid:10823277
Crescente M et al. Gallic acid, a dietary polyphenolic component, blunts the inhibition of platelet COX-1 by aspirin: preliminary in-vitro findings. 2007 Thromb. Haemost. pmid:17549313
Undas A et al. Lack of aspirin-induced decrease in thrombin formation in subjects resistant to aspirin. 2007 Thromb. Haemost. pmid:17549314
Homoncik M et al. Monitoring of aspirin (ASA) pharmacodynamics with the platelet function analyzer PFA-100. 2000 Thromb. Haemost. pmid:10739392
Eldor A et al. Effects of dipyrone on prostaglandin production by human platelets and cultured bovine aortic endothelial cells. 1983 Thromb. Haemost. pmid:6346571
Menys VC and Davies JA Selective inhibition of thromboxane synthetase with dazoxiben - basis of its inhibitory effect on platelet adhesion. 1983 Thromb. Haemost. pmid:6346575
Hampton KK et al. Coagulation, fibrinolytic and platelet function in patients on long-term therapy with aspirin 300 mg or 1,200 mg daily compared with placebo. 1990 Thromb. Haemost. pmid:2073296
Vejar M et al. Dissociation of platelet activation and spontaneous myocardial ischemia in unstable angina. 1990 Thromb. Haemost. pmid:2363117
Dragani A et al. Oxidative stress and platelet activation in subjects with moderate hyperhomocysteinaemia due to MTHFR 677 C→T polymorphism. 2012 Thromb. Haemost. pmid:22782530
Vezza R et al. Antivasoconstrictor and antiaggregatory activities of picotamide unrelated to thromboxane A2 antagonism. 1997 Thromb. Haemost. pmid:9408024
Lessiani G et al. Inflammation, oxidative stress and platelet activation in aspirin-treated critical limb ischaemia: beneficial effects of iloprost. 2011 Thromb. Haemost. pmid:21103664
Greer IA et al. Platelet activation in allergic asthma. 1985 Thromb. Haemost. pmid:2931855
Hohlfeld T et al. Antiplatelet effects of ticlopidine are reduced in experimental hypercholesterolemia. 1994 Thromb. Haemost. pmid:7513092
Han P et al. Verapamil and collagen-induced platelet reactions--evidence for a role for intracellular calcium in platelet activation. 1983 Thromb. Haemost. pmid:6415847
Turpeinen AM et al. Replacement of dietary saturated by unsaturated fatty acids: effects of platelet protein kinase C activity, urinary content of 2,3-dinor-TXB2 and in vitro platelet aggregation in healthy man. 1998 Thromb. Haemost. pmid:9798986
Guthikonda S et al. Increased platelet sensitivity among individuals with aspirin resistance - platelet aggregation to submaximal concentration of arachidonic acid predicts response to antiplatelet therapy. 2008 Thromb. Haemost. pmid:18612542
Gresele P et al. Platelet activation markers in patients with peripheral arterial disease--a prospective comparison of different platelet function tests. 1997 Thromb. Haemost. pmid:9423790
Davì G et al. The effect of two low doses of aspirin on whole blood thromboxane and prostacyclin generation in healthy subjects. 1983 Thromb. Haemost. pmid:6417815
Dale J et al. The effect of a thromboxane synthetase inhibitor, dazoxiben, and acetylsalicylic acid on platelet function and prostaglandin metabolism. 1983 Thromb. Haemost. pmid:6689091
Hornby EJ et al. The inhibitory effect of GR32191, a thromboxane receptor blocking drug, on human platelet aggregation, adhesion and secretion. 1989 Thromb. Haemost. pmid:2529661
Bar J et al. The regulation of platelet aggregation in vitro by interleukin-1beta and tumor necrosis factor-alpha: changes in pregnancy and in pre-eclampsia. 1997 Thromb. Haemost. pmid:9364994
Husted SE et al. Intravenous acetylsalicylic acid--dose-related effects on platelet function and fibrinolysis in healthy males. 1992 Thromb. Haemost. pmid:1412171
Wang JS et al. Effect of strenuous arm exercise on oxidized-LDL-potentiated platelet activation in individuals with spinal cord injury. 2000 Thromb. Haemost. pmid:10928481
Subbiah MT et al. Studies of aggregation and thromboxane B2 synthesis in avian thrombocytes: comparison between atherosclerosis-susceptible and resistant breeds. 1980 Thromb. Haemost. pmid:7455983
Zahavi M et al. Abnormal typical pattern of platelet function and thromboxane generation in unstable angina. 1989 Thromb. Haemost. pmid:2531938
Barrett PA and Butler KD Shortening of platelet survival by induced hypercholesterolaemia in rabbits and its prolongation by anagrelide. 1983 Thromb. Haemost. pmid:6648889
Connellan JM et al. Investigation of alternative mechanisms of collagen-induced platelet activation by using monoclonal antibodies to glycoprotein IIb-IIIa and fibrinogen. 1986 Thromb. Haemost. pmid:2940722
Szczeklik A et al. Prolonged bleeding time, reduced platelet aggregation, altered PAF-acether sensitivity and increased platelet mass are a trait of asthma and hay fever. 1986 Thromb. Haemost. pmid:3563961
Falcon CR et al. The in vitro production of thromboxane B2 by platelets of diabetic patients is normal at physiological concentrations of ionized calcium. 1993 Thromb. Haemost. pmid:8259535
Larsen SB et al. Increased platelet aggregation and serum thromboxane levels in aspirin-treated patients with prior myocardial infarction. 2012 Thromb. Haemost. pmid:22534977
Cattaneo M et al. Conditions influencing the interaction of asialo von Willebrand factor with human platelets--the effects of external ionized calcium concentration and the role of arachidonate pathway. 1988 Thromb. Haemost. pmid:3146144
Fimognari FL et al. Nocturnal rise of urinary thromboxane B 2 in patients with coronary artery disease. 2005 Thromb. Haemost. pmid:15735822
De Caterina R et al. Organic nitrates: direct antiplatelet effects and synergism with prostacyclin. Antiplatelet effects of organic nitrates. 1988 Thromb. Haemost. pmid:3291182
Teng CM and Ko FN Comparison of the platelet aggregation induced by three thrombin-like enzymes of snake venoms and thrombin. 1988 Thromb. Haemost. pmid:3291184
Davì G et al. Demonstration of Rickettsia Conorii-induced coagulative and platelet activation in vivo in patients with Mediterranean spotted fever. 1995 Thromb. Haemost. pmid:8584998
Habib A et al. Increased expression of inducible cyclooxygenase-2 in human endothelial cells by antiphospholipid antibodies. 1995 Thromb. Haemost. pmid:8585020
Zahavi J and Zahavi M Enhanced platelet release reaction, shortened platelet survival time and increased platelet aggregation and plasma thromboxane B2 in chronic obstructive arterial disease. 1985 Thromb. Haemost. pmid:3158092
Etulain J et al. Acidosis downregulates platelet haemostatic functions and promotes neutrophil proinflammatory responses mediated by platelets. 2012 Thromb. Haemost. pmid:22159527
Rocca B et al. Increased thromboxane biosynthesis in essential thrombocythemia. 1995 Thromb. Haemost. pmid:8607099
Korbut R et al. On the mechanism of thrombolytic action of thromboxane synthetase inhibitors. 1987 Thromb. Haemost. pmid:3324381
Huang TF et al. Mechanism of action of a potent antiplatelet peptide, triflavin from Trimeresurus flavoviridis snake venom. 1991 Thromb. Haemost. pmid:1665595
Véricel E et al. Moderate oral supplementation with docosahexaenoic acid improves platelet function and oxidative stress in type 2 diabetic patients. 2015 Thromb. Haemost. pmid:25832443
Kyrle PA et al. Evidence for an increased generation of prostacyclin in the microvasculature and an impairment of the platelet alpha-granule release in chronic renal failure. 1988 Thromb. Haemost. pmid:2975407
Spowart K et al. Haemostatic effects of ketorolac with and without concomitant heparin in normal volunteers. 1988 Thromb. Haemost. pmid:3266379
Cerletti C et al. Aspirin kinetics and inhibition of platelet thromboxane generation-relevance for a solution of the "aspirin dilemma". 1985 Thromb. Haemost. pmid:4049312
Hillbom M et al. Platelet thromboxane formation and bleeding time is influenced by ethanol withdrawal but not by cigarette smoking. 1985 Thromb. Haemost. pmid:4049313
Aoki T et al. Difference of (Ca2+)i movements in platelets stimulated by thrombin and TRAP: the involvement of alpha(IIb)beta3-mediated TXA2 synthesis. 1998 Thromb. Haemost. pmid:9657446
McMahon GS et al. Transient heparin-induced platelet activation linked to generation of platelet 12-lipoxygenase. Findings from a randomised controlled trial. 2013 Thromb. Haemost. pmid:23494053
Larsen SB et al. Reduced antiplatelet effect of aspirin is associated with low-grade inflammation in patients with coronary artery disease. 2013 Thromb. Haemost. pmid:23407706
de Boer A et al. Interaction study between Org 10172, a low molecular weight heparinoid, and acetylsalicylic acid in healthy male volunteers. 1991 Thromb. Haemost. pmid:1722918
De Caterina R et al. Equal antiplatelet effects of aspirin 50 or 324 mg/day in patients after acute myocardial infarction. 1985 Thromb. Haemost. pmid:4082090
Davì G et al. Influence of metabolic control on thromboxane biosynthesis and plasma plasminogen activator inhibitor type-1 in non-insulin-dependent diabetes mellitus. 1996 Thromb. Haemost. pmid:8819248
Ding YA et al. Potentiation of adrenaline-induced platelet aggregation by angiotensin II. 1985 Thromb. Haemost. pmid:4089801
Blais N et al. Response to aspirin in healthy individuals. Cross-comparison of light transmission aggregometry, VerifyNow system, platelet count drop, thromboelastography (TEG) and urinary 11-dehydrothromboxane B(2). 2009 Thromb. Haemost. pmid:19652893
Holme S et al. The effect of albumin bound polyunsaturated fatty acids on human platelets. 1984 Thromb. Haemost. pmid:6719386
Brox JH et al. The effect of cod liver oil and corn oil on platelets and vessel wall in man. 1981 Thromb. Haemost. pmid:7031981
Strano A et al. Thromboxane formation by platelets and platelet sensitivity to prostacyclin in patients with acute myocardial infarction. 1981 Thromb. Haemost. pmid:7036402
Butler KD et al. The effects of modulation of prostanoid metabolism on the thoracic platelet accumulation induced by intravenous administration of collagen in the guinea-pig. 1986 Thromb. Haemost. pmid:3105104